CAMBRIDGE, Mass. (December 16, 2013) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Interim Chief Financial Officer, effective December 31, 2013. He replaces Gregory Perry, who, as previously announced, will leave December 30, 2013 to join another local biotechnology company as its Chief Financial and Business Officer.<br /><br />Mr. McAllister served as Vice President, Finance and Administration for Biomet Spine and Bone Healing Technologies from 2007 – 2013. From 1999 – 2007 he served in several capacities, including Director of Finance, Worldwide Operations, for Depuy Inc, and from 1984 – 1999 he worked in several capacities at Howmedica, a Pfizer subsidiary that was sold to Stryker in 1998.<br /><br />Michael Astrue, InVivo’s Interim Chief Executive Officer, said, “Steve McAllister brings expertise in both finance and in the operations of device companies. I am confident that he will provide the same judgment, integrity and strategic vision provided by Greg Perry during our initial repositioning of InVivo.”